Sign In
Buy BLUE
$4.97
+0 (+0%)
At Close: Aug 29, 2025
Here's the Hot Target for Multiple Myeloma Drugs
03:44pm, Saturday, 12'th Dec 2020
Drugmakers are targeting B-cell maturation antigen in different ways.
Watch Out bluebird bio, CRISPR Is on Your Heels
03:39pm, Saturday, 12'th Dec 2020
The battle for beta thalassemia and sickle cell disease patients is heating up.
3 Stocks That Are Giving Their Investors Coal in Their Stockings
07:20am, Saturday, 12'th Dec 2020
Naughty or nice, shareholders aren't getting anything on their wish lists from these stocks this year.
Shape Therapeutics Announces Appointment of Gary Fortin as Chief Operating Officer
08:00am, Tuesday, 08'th Dec 2020
SEATTLE--(BUSINESS WIRE)-- #shapelife--Shape Therapeutics, Inc. (ShapeTX), a next-generation gene therapy company with an industry-leading RNA targeting technology platform, announces today the appoin
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) announced that new data from Group C of its ongoing Phase 1/2 HGB-206 study of investigational LentiGlobin™ gene therapy (bb1111)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today presented updated long-term efficacy and safety results reflecting up to six years of data for betibeglogene autotemcel gene
PRINCETON, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BLUE #ASH2020--BMS and bluebird bio Present Data Highlighting Anti-BCMA CAR T Cell Therapy, Ide-cel, in Relapsed and Refractory Multiple Myelom
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA) and bluebird bio, Inc. (NASDAQ: BLUE) today announced an exclusive clinical trial collaboration to evaluate the utility of MGTA-1
5 Under-the-Radar Tickers That Will Stomp the Market in 2021
06:32am, Thursday, 19'th Nov 2020
Investors are hyper-focused on COVID-19 right now, but once vaccines for the virus have been approved, other healthcare stocks will start to zoom forward.
SHAREHOLDER ALERT: Investigation of bluebird Announced by Holzer & Holzer, LLC
10:04am, Wednesday, 11'th Nov 2020
Atlanta, Georgia--(Newsfile Corp. - November 11, 2020) - Holzer & Holzer, LLC is investigating whether bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE) complied with federal securities
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, Inc. - BLUE
09:29pm, Tuesday, 10'th Nov 2020
NEW YORK, Nov. 10, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE). Such investors are advised to c
bluebird bio Announces November Investor Events
08:00am, Tuesday, 10'th Nov 2020
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the following upcoming investor conferences: Cowen 2020 IO
Can bluebird bio Recover From Another Major Setback?
06:23am, Friday, 06'th Nov 2020
Another manufacturing issue set the biotech's sickle cell disease program back much further than investors had hoped.
Here's Why Bluebird's Shares Fell Out of the Nest Today
02:27pm, Thursday, 05'th Nov 2020
A delay in submitting its sickle cell treatment to the FDA will push back a major source of future revenue.
Bluebird bio's stock plunges after submission delay of sickle cell disease treatment
10:11am, Thursday, 05'th Nov 2020
Shares of Bluebird bio Inc. traded 15.1% into the red in morning trading Thursday, after the gene therapy company pushed back the U.S. submission for approval of its sickle cell disease treatment Lent
